| First Author | Schulert GS | Year | 2018 |
| Journal | Int Immunol | Volume | 30 |
| Issue | 5 | Pages | 195-203 |
| PubMed ID | 29420734 | Mgi Jnum | J:261421 |
| Mgi Id | MGI:6155572 | Doi | 10.1093/intimm/dxy012 |
| Citation | Schulert GS, et al. (2018) Convergent pathways of the hyperferritinemic syndromes. Int Immunol 30(5):195-203 |
| abstractText | Hyperferritinemia and pronounced hemophagocytosis help distinguish a subset of patients with a particularly inflammatory and deadly systemic inflammatory response syndrome. Two clinically similar disorders typify these hyperferritinemic syndromes: hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). HLH is canonically associated with a complete disturbance of perforin/granzyme-mediated cytotoxicity, whereas MAS occurs in the context of the related rheumatic diseases systemic juvenile idiopathic arthritis and adult-onset Still's disease, with associated IL-1 family cytokine activation. In practice, however, there are accumulating lines of evidence for innate immune dysregulation in HLH as well as partial impairments of cytotoxicity in MAS, and these mechanisms likely represent only a fraction of the host and environmental factors driving hyperferritinemic inflammation. Herein, we present new findings that highlight the pathogenic differences between HLH and MAS, two conditions that present with life-threatening hyperinflammation, hyperferritinemia and hemophagocytosis. |
